Business Context and Reporting Period
Company: The Cooper Companies, Inc. (Cooper)
Filing Type: Form 10-K (Annual Report)
Period Ended: October 31, 2005
Business Overview: Cooper develops, manufactures, and markets healthcare products through two primary business units: CooperVision (CVI), a global manufacturer of soft contact lenses, and CooperSurgical (CSI), a provider of medical devices for women's healthcare (obstetrics and gynecology). The fiscal year was defined by the acquisition of Ocular Sciences, Inc. (Ocular) on January 6, 2005, for approximately $1.2 billion, which significantly expanded CVI's product portfolio and geographic reach.
Key Financial Metrics
| Metric | Fiscal 2005 | Fiscal 2004 |
|---|---|---|
| Net Sales | $806.6 million | $490.2 million |
| Gross Profit | $496.8 million | $315.8 million |
| Gross Margin | 62% | 64% |
| Operating Income | $135.8 million | $116.8 million |
| Operating Margin | 17% | 24% |
| Net Income | $91.7 million | $92.8 million |
| Diluted EPS | $2.04 | $2.59 |
| Operating Cash Flow | $183.8 million | $101.2 million |
| Total Debt | $704.9 million | $165.7 million |
| Stockholders' Equity | $1,273.2 million | $544.2 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 65% to $806.6 million, driven primarily by the inclusion of Ocular's net sales. CVI sales grew 80% (77% in constant currency), while CSI sales grew 7%.
- Profitability: While operating income increased 16%, the operating margin declined from 24% to 17%. This compression was due to a $16.8 million inventory step-up adjustment, a $20 million write-off of acquired in-process R&D, and $12.9 million in restructuring/integration costs.
- Earnings Per Share: Diluted EPS decreased 21% to $2.04, despite stable net income, due to a 26% increase in the number of dilutive shares resulting from the stock portion of the Ocular acquisition.
- Debt Structure: Total debt increased to $704.9 million from $165.7 million to fund the Ocular acquisition. The company replaced its $225 million credit facility with a $750 million agreement.
- Segment Performance: CVI operating income rose to $135.5 million from $106.6 million. CSI operating income declined to $17.4 million from $20.9 million due to investments in sales force expansion and facility shutdowns.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Management Commentary
- Product Pipeline: CVI plans to introduce new silicone hydrogel lenses (Biofinity) and expand single-use and toric offerings in 2006. CSI expects to expand its hospital segment presence following the November 2005 acquisitions of NeoSurg Technologies and Inlet Medical.
- Integration: The company expects to complete the integration of Ocular through 2007, with total restructuring costs estimated between $25 million and $30 million.
- Accounting Changes: Cooper will adopt SFAS 123R (Share-Based Payment) in the first quarter of fiscal 2006, which is expected to have a material impact on earnings per share.
Risks and Contingencies
- Internal Control Material Weakness: The company identified a material weakness in internal controls related to the accounting for acquisitions. This resulted in the restatement of quarterly financial data for the first three quarters of 2005 to correct purchase price allocation errors regarding intangible assets.
- IRS Litigation: The IRS has asserted a deficiency of $44.8 million in taxes plus penalties related to Ocular's pre-acquisition years (1999-2001). Cooper intends to vigorously contest this claim.
- Competition: Intense competition in the contact lens market, particularly regarding newer silicone hydrogel technologies from larger competitors (Johnson & Johnson, CIBA Vision, Bausch & Lomb).
- Regulatory: Significant risks associated with FDA approvals for new products and compliance with global regulatory standards.
Investor Verification Checklist
- Restatement Details: Verify the specific adjustments made to the purchase price allocation for Ocular and the impact on amortization expenses in the restated quarterly reports.
- IRS Dispute Status: Monitor the progress of the Tax Court litigation regarding Ocular's transfer pricing and the potential financial impact of the $44.8 million tax deficiency claim.
- Internal Control Remediation: Review subsequent filings to confirm the timeline and effectiveness of remediation efforts for the identified material weakness in acquisition accounting.
- Debt Covenants: Assess the company's ability to maintain leverage ratios under the new $750 million credit facility, particularly given the high debt load relative to equity.
- Product Launch Success: Track the market acceptance and revenue contribution of the new Biofinity silicone hydrogel lenses and the integration of NeoSurg/Inlet products into CSI's portfolio.